SUMMARY Twenty prostatic adenocarcinomas, 20 transitional cell carcinomas of the bladder, and 20 colorectal adenocarcinomas were stained for epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphatase. Polyclonal affinity purified first and second antibodies and an indirect immunoperoxidase technique were used. All of the colorectal and bladder tumours and 16/20 prostatic tumours were positive for epithelial membrane antigen. All 20 colorectal, 7/20 bladder, and 5/20 prostatic tumours stained for carcinoembryonic antigen. All of the prostatic adenocarcinomas and none of the colorectal or bladder tumours were positive for prostatic acid phosphatase. These markers may be used to discriminate between tumours arising from these sites.
The histopathological differential diagnosis of widely invasive tumours of prostate, rectum, and bladder may, on occasion, be difficult on morphological grounds alone, especially when the tumours appear undifferentiated on a haematoxylin and eosin preparation. Even though the tumour shows evidence of adenocarcinomatous differentiation, there may be clinical doubt as to which of these organs is the primary source. Furthermore, tumours from these sites may present with nodal metastases or with a pathological fracture, with no definite signs or symptoms to indicate the likely primary site. It is important to make the correct diagnosis, since clinical management and treatment, even if only palliative, is entirely different for these three tumours. This study was designed to investigate the distribution of epithelial membrane antigen (EMA),' carcinoembryonic antigen (CEA),2 and prostatic acid phosphatase in tissue sections3-6 to see whether their expression was sufficiently different to be of value in histological diagnosis.
Accepted for publication 9 August 1984 *Present address: MRC Radiobiology Unit, Harwell, Didcot, Oxford.
EMA' is a large glycoprotein, >440 000 daltons, which has now been partially purified.7 It is recognised by antisera raised against milk fat globule membranes,8 and has been shown in the prostate,' 10 bladder,9 and colon,' I as well as in a wide variety of other benign and malignant lesions.' 9 CEA is an incompletely defined glycoprotein of 180 000 daltons. It was originally found in colorectal carcinomas,2 and has since been shown by immunocytochemical techniques in a number of other sites including the prostate'°-1" and bladder. '2 14-1 Prostatic acid phosphatase is an isoenzyme of acid phosphatase (ortho phosphoric monoester phosphohydrolase, EC 3.1.3-2) of 100 000 daltons'8 and isoelectric point 4 2-5 5. Its enzymic activity is largely destroyed by formalin fixation and processing of tissue into paraffin wax, but specific antisera may be used to demonstrate prostatic acid phosphatase in sections of fixed prostatic tumours and of their metastases, as well as in benign prostatic tissue. 4 6 Cross reactivity with pancreatic islet cells, salivary glands, renal carcinomas and breast carcinomas with some rabbit antisera has been reported, '9-22 although no such activity has been seen in 142 various non-prostatic benign and malignant lesions stained with the affinity purified antibody used in this study (unpublished data 20/20 Without prior knowledge, it was not possible to tell which antibody had been used because the pattern of staining was so similar for the three epithelial markers, although stains for EMA in colorectal tumours were weaker than those for CEA, and stains for CEA in prostatic carcinomas (Fig. 4) were weaker than in colorectal tumours (Fig. 3) . The dilution of primary antibody had been determined on the appropriate positive control tissue-breast carcinoma for EMA, colorectal carcinoma for CEA, and benign prostatic hypertrophy for prostatic acid phosphatase. These differences were therefore relative and could be assessed only in relation to those tissues. No staining was seen with the negative absorbed" controls for any of the three markers.
Discussion
These results confirm previous reports that the demonstration of prostatic acid phosphatase in a tumour is virtually diagnostic of prostatic origin. A further 142 primary and metastatic tumours from a wide variety of sites outside the prostate have been stained with the antibody used here, and none has been positive (unpublished data). Although there were no false positives, the possibility of false negatives cannot be excluded, although in most studies between 93% and 100% of prostatic carcinomas have been found to be positive.5 6"s'29-32 Shevchuk et al-3' found lower rates of positivity using polyclonal goat (83% positive), rabbit (70%), or monoclonal antibodies (59% In the study reported here 5/20 (25%) of the prostatic carcinomas were positive for CEA, a similar figure to the 7/30 (23%) reported by Heidl.'2 This is different from the figures of 16/38 (42%) before absorption with spleen and 1/38 (2-6%) after absorption reported by Purnell et al. '3 1368 The main value of the EMA immunostain in these tumours lies in the distinction of carcinoma from lymphoma or sarcoma.' 938 Fifty six of the 60 carcinomas in this study were positive. Sloane and Ormerod9 found 2/2 prostatic carcinomas, 4/4 bladder tumours, and 6/6 colorectal carcinomas were positive, and using a similar rabbit unpurified antibody Ellis et al'°found EMA in 47/60 (78%) .
Variations in the percentage of positive lumours found in published reports are probably largely due to the use of antisera from different sources, although the immunoperoxidase technique employed and differences in fixation and processing schedules are important. It is advisable for departments which intend to use immunocytochemical stains as an adjunct to diagnostic histopathology to carry out immunostains on a number of tissues fixed and processed at that institution. The incidence of positive tumours stained under local conditions may be ascertained and the potential value of the antibodies established.
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